Assignee
ABBVIE DEUTSCHLAND
DE·77 granted patents·82 pending applications·117 citations·filing 2012–2024
Top patents by PatentIndex Score
159 records- 0194US12098192B2Composition and method for the diagnosis and treatment of iron-related disordersABBVIE DEUTSCHLAND·Filed 2024·Granted Sep 24, 2024·2 cites·20 claims
- 0292US10822403B2Composition and method for the diagnosis and treatment of iron-related disordersABBVIE DEUTSCHLAND·Filed 2018·Granted Nov 3, 2020·5 cites·14 claims
- 0391US12098189B2Composition and method for the diagnosis and treatment of iron-related disordersABBVIE DEUTSCHLAND·Filed 2020·Granted Sep 24, 2024·2 cites·24 claims
- 0487US10118958B2Composition and method for the diagnosis and treatment of iron-related disordersABBVIE DEUTSCHLAND·Filed 2012·Granted Nov 6, 2018·9 cites·38 claims
- 0587US10118926B2Tricyclic quinoline and quinoxaline derivativesABBVIE DEUTSCHLAND·Filed 2013·Granted Nov 6, 2018·10 cites·6 claims
- 0687US9828381B2Substituted pyrazolopyrimidines and method of useABBVIE DEUTSCHLAND·Filed 2016·Granted Nov 28, 2017·3 cites·14 claims
- 0787US9205027B2Process for producing a solid dispersion of an active ingredientABBVIE DEUTSCHLAND·Filed 2013·Granted Dec 8, 2015·9 cites·27 claims
- 0887US8865650B2Therapy for complications of diabetesABBVIE DEUTSCHLAND·Filed 2013·Granted Oct 21, 2014·9 cites·32 claims
- 0986US9394360B2Aβ conformer selective anti-Aβ globulomer monoclonal antibodiesABBVIE DEUTSCHLAND·Filed 2014·Granted Jul 19, 2016·6 cites·2 claims
- 1086US9102722B2Composition and method for the diagnosis and treatment of diseases associated with neurite degenerationABBVIE DEUTSCHLAND·Filed 2013·Granted Aug 11, 2015·6 cites·5 claims
- 1186US2025179159A1Composition and method for the diagnosis and treatment of iron-related disordersABBVIE DEUTSCHLAND·Filed 2024·Application pending·0 cites
- 1284US10106602B2Isolated monoclonal anti-repulsive guidance molecule A antibodies and uses thereofABBVIE DEUTSCHLAND·Filed 2016·Granted Oct 23, 2018·3 cites·11 claims
- 1384US9592231B2Therapy for complications of diabetesABBVIE DEUTSCHLAND·Filed 2014·Granted Mar 14, 2017·6 cites·16 claims
- 1484US8623819B2Therapy for complications of diabetesABBVIE DEUTSCHLAND·Filed 2013·Granted Jan 7, 2014·6 cites·15 claims
- 1583US9605069B2Antibodies against the RGM a protein and uses thereofABBVIE DEUTSCHLAND·Filed 2015·Granted Mar 28, 2017·3 cites·11 claims
- 1683US9527856B2Oxindole compounds carrying a CO-bound spiro substituent and use thereof for treating vasopressin-related diseasesABBVIE DEUTSCHLAND·Filed 2015·Granted Dec 27, 2016·4 cites·38 claims
- 1781US9636398B2Composition and method for the diagnosis and treatment of iron-related disordersABBVIE DEUTSCHLAND·Filed 2012·Granted May 2, 2017·5 cites·16 claims
- 1879US10464976B2Amyloid β(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereofABBVIE DEUTSCHLAND·Filed 2015·Granted Nov 5, 2019·2 cites·31 claims
- 1979US9656955B2Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapyABBVIE DEUTSCHLAND·Filed 2014·Granted May 23, 2017·2 cites·20 claims
- 2079US2024197757A1Pharmaceutical dosage form for oral administration of a bcl 2 family inhibitorABBVIE DEUTSCHLAND·Filed 2023·Application pending·0 cites
- 2177US10047121B2Amyloid-beta binding proteinsABBVIE DEUTSCHLAND·Filed 2015·Granted Aug 14, 2018·2 cites·18 claims
- 2275US9790203B2Inhibitor compounds of phosphodiesterase type 10AABBVIE DEUTSCHLAND·Filed 2013·Granted Oct 17, 2017·2 cites·26 claims
- 2375US9200005B2Inhibitor compounds of phosphodiesterase type 10AABBVIE DEUTSCHLAND·Filed 2014·Granted Dec 1, 2015·3 cites·23 claims
- 2475US9169253B2Tricyclic quinoline and quinoxaline derivativesABBVIE DEUTSCHLAND·Filed 2013·Granted Oct 27, 2015·1 cites·23 claims
- 2575US8895749B24-(4-pyridinyl)-benzamides and their use as rock activity modulatorsABBVIE DEUTSCHLAND·Filed 2013·Granted Nov 25, 2014·2 cites·11 claims
- 2674US9365643B2Antibodies that bind to repulsive guidance molecule A (RGMA)ABBVIE DEUTSCHLAND·Filed 2014·Granted Jun 14, 2016·1 cites·13 claims
- 2773US10836688B2Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcelluloseABBVIE DEUTSCHLAND·Filed 2020·Granted Nov 17, 2020·1 cites·20 claims
- 2873US9856220B2Inhibitor compounds of phosphodiesterase type 10AABBVIE DEUTSCHLAND·Filed 2016·Granted Jan 2, 2018·1 cites·26 claims
- 2973US9573950B2Substituted [1,4]diazepino[6,7,1-ij]quinolines as serotonin 5-HT2C receptor modulatorsABBVIE DEUTSCHLAND·Filed 2015·Granted Feb 21, 2017·2 cites·48 claims
- 3073US9422264B2Carbamate-substituted oxindole derivatives and use thereof for the treatment of vasopressin-dependent diseasesABBVIE DEUTSCHLAND·Filed 2014·Granted Aug 23, 2016·1 cites·21 claims
- 3172US9096619B2Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapyABBVIE DEUTSCHLAND·Filed 2013·Granted Aug 4, 2015·1 cites·20 claims
- 3272US2022110951A1Pharmaceutical dosage form for oral administration of a bcl 2 family inhibitorABBVIE DEUTSCHLAND·Filed 2021·Application pending·0 cites
- 3371US8957089B2Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapyABBVIE DEUTSCHLAND·Filed 2013·Granted Feb 17, 2015·1 cites·15 claims
- 3471US2021238270A1Composition and method for the diagnosis and treatment of diseases associated with neurite degenerationABBVIE DEUTSCHLAND·Filed 2020·Application pending·0 cites
- 3571US2025296917A1Spiro-cyclic amine derivatives as s1p modulatorsABBVIE DEUTSCHLAND·Filed 2024·Application pending·0 cites
- 3671US2021230260A1Antibodies against the rgm a protein and uses thereofABBVIE DEUTSCHLAND·Filed 2020·Application pending·0 cites
- 3771US2022018855A1RGMa Fragment Based Diagnostic AssayABBVIE DEUTSCHLAND·Filed 2021·Application pending·0 cites
- 3870US9487505B2Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing themABBVIE DEUTSCHLAND·Filed 2013·Granted Nov 8, 2016·1 cites·8 claims
- 3970US2021277097A1Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degenerationABBVIE DEUTSCHLAND·Filed 2020·Application pending·0 cites
- 4070US2021093649A1Pharmaceutical dosage form for oral administration of a bcl 2 family inhibitorABBVIE DEUTSCHLAND·Filed 2020·Application pending·0 cites
- 4169US9475808B2Inhibitor compounds of phosphodiesterase type 10AABBVIE DEUTSCHLAND·Filed 2015·Granted Oct 25, 2016·1 cites·33 claims
- 4269US9394363B2Antibodies to receptor of advanced glycation end products (RAGE) and uses thereofABBVIE DEUTSCHLAND·Filed 2012·Granted Jul 19, 2016·1 cites·10 claims
- 4369US9163019B2Inhibitor compounds of phosphodiesterase type 10AABBVIE DEUTSCHLAND·Filed 2014·Granted Oct 20, 2015·1 cites·26 claims
- 4469US2024075114A1IMMUNOGENIC PRODUCTS BASED ON MUTEIN AMYLOID beta (Abeta) AMINO ACID SEQUENCES AND USES THEREOFABBVIE DEUTSCHLAND·Filed 2022·Application pending·0 cites
- 4568US11427598B2Spiro-cyclic amine derivatives as S1P modulatorsABBVIE DEUTSCHLAND·Filed 2020·Granted Aug 30, 2022·0 cites·10 claims
- 4668US9388148B2Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptorABBVIE DEUTSCHLAND·Filed 2014·Granted Jul 12, 2016·1 cites·6 claims
- 4767US9402909B2Pharmaceutical dosage form comprising polymeric carrier compositionABBVIE DEUTSCHLAND·Filed 2014·Granted Aug 2, 2016·1 cites·10 claims
- 4866US8846741B2N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapyABBVIE DEUTSCHLAND·Filed 2012·Granted Sep 30, 2014·1 cites·19 claims
- 4966US2015037348A1Human antibodies that bind human il-12 and methods for producingABBVIE DEUTSCHLAND·Filed 2014·Application pending·0 cites
- 5064US2021353555A1Nanoparticles based on optionally alkoxylated poly(alkyl cyanoacrylates) having a defined degree of polymerizationABBVIE DEUTSCHLAND·Filed 2021·Application pending·0 cites
Showing the top 50 of 159 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →